...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes/metabolism research and reviews >Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes
【24h】

Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes

机译：口服抗糖尿病药联合基础胰岛素治疗对初诊2型糖尿病患者β细胞功能和血糖控制的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Oral anti-diabetes drugs plus basal insulin (OAD+insulin) therapy in patients with newly diagnosed type 2 diabetes might improve β-cell function and result in extended glycaemic remission. This randomised trial compared the effect on β-cell function and diabetes remission rate between oral drug alone or with addition of basal insulin. Methods: One hundred and twenty-nine patients, aged 35-50years, were enrolled between June 2005 and June 2009. For initial correction of hyperglycaemia, patients with fasting plasma glucose ≥9.0mmol/L and HbA 1c≥9.0%, were randomly assigned to therapy with oral drugs+insulin or oral drugs alone. Treatment was stopped after normoglycaemia was maintained for 3months. Patients were then followed-up with diet and physical exercise. Blood glucose, HbA 1c and insulin were measured prior to treatment and at 1-year follow-up. Results: More patients achieved target glycaemic control in the oral drugs+insulin group [98.3% (58 of 59)] in less time [(10.4±2.5) days] than those in the oral drug group [95.7% (67 of 70) and (12.4±3.4) days]. At 1-year follow-up, more patients maintained target glycaemia without any drugs in the oral drug+insulin group than in the oral drug group [37.9% (22 of 58) vs 20.9% (14 of 67)]. Both treatments improved homeostasis model assessment-β (HOMA-β) and homeostasis model assessment-insulin resistance (HOMA-IR) significantly. They had similar effects on insulin resistance [lg(HOMA-IR): (0.50±0.09) vs (0.48±0.09), p=0.23]. However, oral drugs+insulin could recover β-cell function much more than OAD alone could [lg(HOMA-β): (2.17±0.14) vs (2.11±0.13), p=0.03]. Conclusion: In newly diagnosed type 2 diabetes, therapy with oral drugs+insulin has had favourable outcomes on recovery and maintenance of β-cell function and protracted glycaemic remission compared with treatment with oral drugs alone.
机译：背景：在新诊断的2型糖尿病患者中，口服抗糖尿病药物加基础胰岛素（OAD +胰岛素）治疗可能会改善β细胞功能并导致血糖缓解期延长。这项随机试验比较了单独口服药物或添加基础胰岛素对β细胞功能和糖尿病缓解率的影响。方法：2005年6月至2009年6月，纳入年龄在35至50岁之间的129例患者。为初步纠正高血糖症，随机分配空腹血糖≥9.0mmol/ L和HbA1c≥9.0％的患者用口服药物+胰岛素或单独口服药物进行治疗。维持血糖正常3个月后停止治疗。然后对患者进行饮食和体育锻炼的随访。在治疗前和一年的随访中测量血糖，HbA 1c和胰岛素。结果：与口服药物组相比，在更少的时间[（10.4±2.5）天]内，口服药物+胰岛素组[98.3％（59 of 58）]达到目标血糖控制的患者更多[95.7％（67 of 70）]和（12.4±3.4）天]。在1年的随访中，与口服药物组相比，口服药物+胰岛素组中没有任何药物维持目标血糖的患者要多于口服药物组[37.9％（58中的22）对20.9％（67中的14）]。两种治疗均显着改善了稳态模型评估-β（HOMA-β）和稳态模型评估-胰岛素抵抗（HOMA-IR）。它们对胰岛素抵抗的作用相似[1g（HOMA-IR）：( 0.50±0.09）vs（0.48±0.09），p = 0.23]。然而，口服药物+胰岛素比单独使用OAD可以恢复更多的β细胞功能[lg（HOMA-β）：( 2.17±0.14）vs（2.11±0.13），p = 0.03]。结论：在新诊断的2型糖尿病中，与单独口服药物相比，口服药物+胰岛素疗法在恢复和维持β细胞功能以及延长血糖释放方面具有良好的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号